Spero Therapeutics (SPRO) Operating Leases (2019 - 2026)
Spero Therapeutics (SPRO) reported Operating Leases of $507000.0 for Q1 2026, down 76.58% on a YoY basis from $2.2 million in Q1 2025, and down 46.01% quarter-over-quarter from $939000.0 in Q4 2025.
Spero Therapeutics (SPRO) Operating Leases (2019 - 2026) Analysis & Trends
Spero Therapeutics has reported Operating Leases for 8 years, with the latest figure at $507000.0 in Q1 2026.
- For the quarter ending Q1 2026, Operating Leases fell 76.58% year-over-year to $507000.0; the trailing twelve-month figure through Mar 2026 stood at $507000.0 (down 76.58% YoY), and the FY2025 full-year result was $939000.0, down 63.19% from the prior year.
- Operating Leases for Q1 2026 stood at $507000.0, down from $939000.0 in the prior quarter.
- The five-year high for Operating Leases was $5.7 million in Q1 2022, with the low at $507000.0 in Q1 2026.
- Historically, Operating Leases has averaged $3.4 million across 5 years, with a median of $3.5 million in 2024.
- Annual changes were most pronounced in 2022 — Operating Leases fell 14.06% — and 2026, when it tumbled 76.58%.
- Spero Therapeutics' Operating Leases stood at $5.0 million in 2022, then declined by 22.84% to $3.8 million in 2023, then plunged by 33.31% to $2.6 million in 2024, then plunged by 63.19% to $939000.0 in 2025, then tumbled by 46.01% to $507000.0 in 2026.
- The last three Operating Leases figures came in at $507000.0 (Q1 2026), $939000.0 (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Spero Therapeutics | 162.39 Mn | 106.26 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 507,000.00 |
| Dec 31, 2025 | 939,000.00 |
| Sep 30, 2025 | 1.45 Mn |
| Jun 30, 2025 | 1.77 Mn |
| Mar 31, 2025 | 2.17 Mn |
| Dec 31, 2024 | 2.55 Mn |
| Sep 30, 2024 | 2.88 Mn |
| Jun 30, 2024 | 3.21 Mn |
| Mar 31, 2024 | 3.52 Mn |
| Dec 31, 2023 | 3.83 Mn |
| Sep 30, 2023 | 4.12 Mn |
| Jun 30, 2023 | 4.41 Mn |
| Mar 31, 2023 | 4.69 Mn |
| Dec 31, 2022 | 4.96 Mn |
| Sep 30, 2022 | 5.22 Mn |
| Jun 30, 2022 | 5.47 Mn |
| Mar 31, 2022 | 5.73 Mn |
| Dec 31, 2021 | 5.97 Mn |
| Sep 30, 2021 | 6.19 Mn |
| Jun 30, 2021 | 6.43 Mn |